288 related articles for article (PubMed ID: 26173780)
1. Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.
Chakrabarti G
Radiat Oncol; 2015 Jul; 10():145. PubMed ID: 26173780
[TBL] [Abstract][Full Text] [Related]
2. KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.
Nagy Á; Pongor LS; Szabó A; Santarpia M; Győrffy B
Int J Cancer; 2017 Feb; 140(4):930-937. PubMed ID: 27859136
[TBL] [Abstract][Full Text] [Related]
3. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells.
Liu H; Hu X; Zhu Y; Jiang G; Chen S
Tumour Biol; 2016 Jun; 37(6):7287-93. PubMed ID: 26666824
[TBL] [Abstract][Full Text] [Related]
5. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
6. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
7. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
[TBL] [Abstract][Full Text] [Related]
9. Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.
Hames ML; Chen H; Iams W; Aston J; Lovly CM; Horn L
Lung Cancer; 2016 Feb; 92():29-34. PubMed ID: 26775593
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
11. Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits.
Wu Z; Liu Z; Jiang X; Mi Z; Meng M; Wang H; Zhao J; Zheng B; Yuan Z
J Exp Clin Cancer Res; 2019 Aug; 38(1):341. PubMed ID: 31387622
[TBL] [Abstract][Full Text] [Related]
12. Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer.
Kim EY; Jung JY; Kim A; Kim K; Chang YS
BMC Cancer; 2017 Jul; 17(1):467. PubMed ID: 28679377
[TBL] [Abstract][Full Text] [Related]
13. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
15. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
Wang S; An T; Wang J; Zhao J; Wang Z; Zhuo M; Bai H; Yang L; Zhang Y; Wang X; Duan J; Wang Y; Guo Q; Wu M
Clin Cancer Res; 2010 Feb; 16(4):1324-30. PubMed ID: 20145159
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
[TBL] [Abstract][Full Text] [Related]
17. Cytosolic malic enzyme and glucose-6-phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance.
Ran M; Zhou Y; Guo Y; Huang D; Zhang SL; Tam KY
FEBS J; 2023 Oct; 290(19):4792-4809. PubMed ID: 37410361
[TBL] [Abstract][Full Text] [Related]
18. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
[TBL] [Abstract][Full Text] [Related]
19. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
20. MiR-195 suppresses non-small cell lung cancer by targeting CHEK1.
Liu B; Qu J; Xu F; Guo Y; Wang Y; Yu H; Qian B
Oncotarget; 2015 Apr; 6(11):9445-56. PubMed ID: 25840419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
